Purpose It has been reported that lysyl oxidase (LOX) is a hypoxia-responsive factor and is associated with the malignant progression of carcinoma. The aim of this study was to clarify the relationship between the epithelialmesenchymal transition (EMT) and LOX in gastric cancer cells under hypoxia. Methods Two gastric cancer cell lines, OCUM-2MD3 and OCUM-12, were used in an in vitro study. The effect of LOX small interfering RNA (siRNA) on the EMT and motility of gastric cancer cells under hypoxic condition was analyzed by reverse transcription PCR, Western blot, a wound-healing assay, and an invasion assay. Correlations between LOX expression and the clinicopathological features of 544 patients with gastric carcinoma were examined immunohistochemically.
Introduction
Hypoxic environments are randomly scattered throughout carcinomas owing to the heterogeneous nature of angiogenesis [1] . Although hypoxia is cytotoxic to both cancer cells and normal cells, some types of cancer cells acquire characteristics that allow them to survive and progress in a hypoxic environment [2] . Hypoxia is considered to be associated with aggressive tumor phenotypes of gastric carcinomas [3] , including the ability to metastasize [4] . Hypoxia is clinically associated with metastasis and poor patient outcome, although the underlying processes remain unclear [5] . It has been reported that hypoxia promotes tumor epithelial-mesenchymal transition (EMT), invasion, and metastasis, largely mediated by the targets of hypoxiainducible factors (HIFs) [6] . HIF-1a, a subunit of HIF-1, mediated hypoxia-induced tumor cell migration and invasion through Notch signaling in colon and ovarian cancer cells [7] . It is thus important for the development of cancer treatments to clarify the mechanism responsible for the aggressive tumor phenotypes induced by hypoxia.
Lysyl oxidase (LOX) is synthesized as a 50-kDa proenzyme (pro-LOX) that is secreted and then cleaved in the extracellular space by bone morphogenetic protein 1 to form a 30-kDa, mature, active enzyme and an 18-kDa propeptide (LOX-PP) [8, 9] . LOX and its family members, LOX-like 1-4, oxidize lysine residues in collagens and elastin [10] , which results in covalent cross-linking and stabilization of these extracellular matrix structural components, conferring on collagen and elastic fibers much of their tensile strength [11] . LOX families are involved in a variety of pathological processes related to connective tissue [12, 13] , including cancer progression and metastasis [11, 14] . Involvement of the LOX family is widely accepted as a poor prognostic factor for patients with cancer [15] [16] [17] [18] [19] [20] . By contrast, Kaneda et al. [21] reported that LOX is a tumor suppressor gene inactivated by heavy methylation of the 5 0 untranslated region and loss of heterozygosity in gastric cancers, and several studies have reported that LOX-PP has tumor suppressor activity [22] [23] [24] . Both downregulation and upregulation of LOX in tumor tissues and cancer cell lines have been described [25] [26] [27] [28] , suggesting a paradoxical role for LOX as a tumor suppressor [21, 29] as well as a metastasis promoter gene [30, 31] .
In addition, Erler et al. [31] have reported that LOX is related to hypoxia-induced metastasis in breast cancer. Several studies have reported associations between hypoxia and LOX in other types of cancer [25, 32] , and HIF-1 is a critical regulator of breast cancer metastatic niche formation through induction of multiple members of the LOX family, including LOX, LOX-like 2, and LOX-like 4 [30] . In addition, hypoxia-induced LOX modulates tumor metastasis through activation of b 1 integrin signaling [33] [34] [35] .
We previously reported that hypoxia stimulates the EMT. resulting in a highly invasive form of gastric cancer in vitro and that transforming growth factor b (TGFb) is one of the factors regulating EMT under hypoxia [36, 37] . However, the mechanisms of EMT under hypoxic conditions have not been fully revealed, and we speculated LOX is associated with gastric cancer progression in a hypoxic environment.
The aim of this study was to identify the relationship between hypoxic EMT and LOX in gastric cancer.
Materials and methods

Cell lines
We used two gastric cancer cell lines, OCUM-2MD3 [38] and OCUM-12 [39] , derived from diffuse-type gastric carcinomas. The culture medium consisted of Dulbecco's modified Eagle's medium (DMEM; Wako, Osaka, Japan) with the addition of 10 % fetal bovine serum (FBS; Nichirei., Tokyo, Japan), 100 IU/ml penicillin (Wako), 100 mg/ml streptomycin (Wako), and 0.5 mM sodium pyruvate (Wako). Cells were cultured at 37°C in 21 % O 2 (normoxia) or 1 % O 2 (hypoxia) in a modular incubator chamber (Hirasawa, Tokyo, Japan) with 5 % CO 2 and balanced with N 2 gas.
Preparation of conditioned medium
We prepared conditioned medium from OCUM-12 and OCUM-2MD3 cells, which were transfected with LOX small interfering RNA (siRNA; siLOX#1 and siLOX#2) or negative siRNA. To obtain conditioned medium, gastric cancer cells were washed with phosphate-buffered saline and then incubated for an additional 48 h in DMEM without FBS. Next, conditioned medium was collected from each dish. The supernatant was stored as conditioned medium at -20°C until use.
Design of siRNA
The siRNA and nontargeting siRNA (negative siRNA) were purchased from Ambion (Life Technologies, Carlsbad, CA ,USA): HIF1A (which encodes HIF-1a) siRNA (siHIF-1a; ID s6539), siLOX#1 (ID s8254), and siLOX#2 (ID s8255). OCUM-2MD3 and OCUM-12 cells were prepared at 50-60 % confluence in six-well dishes. The transfection mixture was prepared by addition of 150 lL of Opti-MEM including 9 lL of Lipofectamine RNA iMAX reagent (Life Technologies) to 150 lL of Opti-MEM including 90 pmol of siRNA, followed by incubation for 5 min at room temperature. Finally, the transfection mixture was added to a six-well dish containing 1.7 mL of DMEM with 2 % FBS. Twenty-four hours after transfection, quantitative reverse transcription (RT) polymerase chain reaction (PCR) and Western blot were done and conditioned medium was prepared. 
Quantitative real-time RT-PCR
Morphological changes
Cancer cells were cultured under normoxic or hypoxic conditions with negative siRNA, siLOX#1, or siLOX#2 for 24 h, and cell morphology was observed microscopically. EMT was determined when polygonal or spindle-shaped cancer cells were found by phase-contrast microscopy.
Western blot analysis
Expression levels of LOX, E-cadherin, and vimentin were examined as follows. Cell lysates or condition media were collected after different treatments. Cancer cells were incubated under normoxic conditions without treatment or under hypoxic conditions with negative siRNA, siLOX#1, siLOX#2, or siHIF-1a for 48 h. After the protein concentration of each sample had been adjusted, electrophoresis was done using 10 % tris(hydroxymethyl)aminomethaneglycine gels (Life Technologies). The protein bands obtained were transferred to an Immobilon-P transfer membrane (Amersham, Aylesbury, UK). Then, the membrane was placed in a solution of phosphate-buffered saline and Tween 20 containing anti-LOX antibody (Novus Biologicals, Littleton, CO, USA), anti-E-cadherin antibody (Cell Signaling, Danvers, MA, USA), and anti-vimentin antibody (Abcam, Cambridge, MA, USA) and allowed to react at room temperature for 2 h. The levels of specific proteins in each lysate were detected by enhanced chemiluminescence with ECL Plus (Amersham) followed by autoradiography.
Wound-healing assay
Gastric cancer cells were cultured in 96-well plates (Essen ImageLock; Essen Instruments, Birmingham, UK). After the cells had reached semiconfluence, a wound was created in the cell monolayer with a 96-well WoundMaker (Essen Bioscience, Ann Arbor, MI, USA). Cancer cells were cultured in DMEM with 2 % FBS. Scratched fields were pictured every 3 h, and were monitored with an IncuCyte live-cell imaging system and software (Essen Instruments). The degree of cell migrations was analyzed 12 h after wound treatment as a percentage of wound confluence. The mean of four fields was calculated as the sample value.
Invasion assay
The in vitro invasiveness was measured by a two-chamber Matrigel invasion assay involving chemotaxis cell chambers (Millipore, Billerica, MA, USA) with a 12-lm pore membrane filter coated with 50 lg of Matrigel (upper chamber) in a 24-well culture plate (lower chamber), as previously reported [40] . Gastric cancer cells (2 9 10 4 cells per 200 lL per chamber) were seeded in the upper chamber, and 500 lL of DMEM with 2 % FBS was added to the lower chamber. After incubation in 20 % O 2 (normoxia) or 1 % O 2 (hypoxia) for 22 h, cancer cells that invaded the lower surface of the membrane through a filter were stained by Diff-Quik (Sysmex, Kobe, Japan), and were manually counted under a microscope at 9200 magnification. Six randomly chosen fields were counted for each assay. The mean of six fields was calculated as the sample value.
Clinical materials
A total of 544 patients who had undergone a resection of the primary tumor and were confirmed histologically to have sporadic gastric cancer were enrolled in this study. Of the 544 patients with resectable cancer, 442 underwent a potentially curative R0 resection; the remaining 102 patients were treated with a palliative resection. None of the patients had undergone preoperative radiation therapy or chemotherapy. The pathological diagnoses and classifications were made according to the Union for International Cancer Control TNM classification of malignant tumors. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki. This study was approved by the Osaka City University Ethics Committee. Written informed consent was obtained from all patients.
Immunohistochemical determination of LOX
An anti-LOX antibody (Abcam, Cambridge, MA, USA) and an anti-carbonic anhydrase 9 (CA9) antibody (1: 1000; NB 100-417, Novus Biologicals, Littleton, CO, USA) were used. The methods used for the immunohistochemical determination are described in the kit manufacturer's instructions, as previously reported [14] . LOX expression was evaluated by the intensity of staining and the percentage of stained cancer cells at the invading tumor front: intensity was given a score ranging from 0 to 2 (0 = no intensity, 1 = weak to moderate intensity, 2 = intense intensity), and the percentage of immunopositive cells was given a score ranging from 0 to 4 (0 = 0 %, 1 = 1-30 %, 2 = 31-60 %, 3 = 61-80 %, 4 = 81-100 %). The two scores were multiplied to obtain the final result, ranging from 0 to 8. Expression was considered positive when the scores was 5 or more and was considered negative when the score was 4 or less. CA9 expression was evaluated as previously reported [41] . Evaluation was done by two double-blinded independent observers who were unaware of the clinical data and outcome. When there was a discrepant evaluation between the two independent observers, the evaluation was rechecked and discussed.
Statistical analysis
The chi square test or Fisher's exact was used to determine the significance of differences between covariates. Survival durations were calculated with the Kaplan-Meier method and analyzed by the log-rank test to compare cumulative survival durations among patient groups. In addition, the Cox proportional hazards model was used to compute univariate hazard ratios for the study parameters. In all of the tests, p \ 0.05 was defined as statistically significant. The SPSS software program (SPSS Japan, Tokyo, Japan) was used for the analyses. In vitro data are expressed as the mean ± standard deviation, and significant difference was analyzed by the unpaired Student's t test.
Results
Effect of hypoxic conditions on the LOX expression of gastric cancer cells and the secretion of LOX Hypoxic conditions increased the number of polygonal or spindle-shaped cells resulting from EMT without siRNA treatment or with negative siRNA treatment in both OCUM-12 and OCUM-2MD3 cells after 24 h in culture compared with normoxic conditions (Fig. 1a, b) . The expression of glycosylated LOX (about 58 kDa), which is the form of LOX before secretion [34, 42] , was increased by hypoxia in both messenger RNA (mRNA) level and protein level compared with that under normoxia. Cells were transfected with siLOX#1, siLOX#2, or with unspecific siRNA used as a negative control. Treatment with siLOX#1 or siLOX#2 significantly (p \ 0.001) downregulated LOX mRNA levels. Compared with the negative siRNA, siLOX#1 and siLOX#2 decreased the expression of glycosylated LOX of OCUM-2MD3 and OCUM-12 cells under hypoxia (Fig. 1c, e) . Furthermore, hypoxic conditions increased the secretion of mature LOX (about 30 kDa) in the conditioned medium prepared from OCUM-12 and OCUM-2MD3 cells; this was decreased with treatments with siLOX#1 and siLOX#2 (Fig. 1f) .
Effect of hypoxic conditions on the EMT of gastric cancer cells
The EMT of cancer cells induced by hypoxia was inhibited by treatment with two LOX siRNAs, whereas no change was observed by treatment with both LOX siRNAs under normoxic condition (Fig. 1a, b) . Hypoxia downregulated CDH1 mRNA expression level in both OCUM-12 cells and OCUM-2MD3 cells, whereas it upregulated VIM mRNA expression in OCUM-12 cells. LOX knockdown by LOX siRNAs significantly increased the CDH1 expression levels in both OCUM-12 cells and OCUM-2MD3 cells under hypoxia. VIM mRNA expression was significantly decreased by LOX siRNA in OCUM-2MD3 and OCUM12 cells (Fig. 1d) . Similar results were found for protein levels by Western blot analysis (Fig. 1e) . In hypoxia, LOX mRNA expression was significantly decreased by siHIF-1a treatment in both OCUM-12 cells (50 % decreased) and OCUM-2MD3 cells (36 % decreased) cells (Fig. 2a) . HIF1A knockdown also decreased the protein levels of glycosylated LOX in OCUM-12 and OCUM-2MD3 cells (Fig. 2b) .
Effect of LOX siRNA on the migration and invasion abilities of gastric cancer cells Figure S1 shows a representative phase-contrast image of the wound-healing assay in hypoxia. The number of migrating OCUM-12 cells was significantly (p \ 0.01) decreased by siLOX transfection (Fig. 3a) . Figure S2 Relationship between clinicopathological features and the expression of LOX in gastric cancer LOX expression of cancer cells was observed in the cytoplasm and nucleus, but mainly in the cytoplasm (Fig. 4a) . Table 1 shows the correlation between the clinicopathological features and LOX expression in cancer cells. Among the 544 gastric cancers examined, 287 (53 %) were positive for LOX expression in cancer cells. LOX expression was correlated significantly with age, macroscopic type 4 cancers, T invasion (T2-T4), lymph node metastasis, intestinal-type cancers, lymphatic invasion, venous invasion, peritoneal metastasis, peritoneal cytology, and CA9 expression, but not with gender, infiltration, or hepatic metastasis. LOX expression was associated with the expression of the hypoxic marker CA9. Figure S3 shows that CA9-positive tissue exhibited heterogeneous stainability similar to that of LOXpositive tissue.
Correlation between overall survival and LOX expression Figure 4b shows that the overall survival of patients (n = 543) with LOX-positive cancer cells was significantly worse than that of patients with LOX-negative cancer cells (p \ 0.001). Univariate analysis revealed that the overall survival of patients was significantly correlated with LOX expression, macroscopic type 4 cancers, diffuse-type cancers, T invasion (T2-T4), lymph node metastasis, lymphatic invasion, venous invasion, infiltration, hepatic metastasis, peritoneal metastasis, and peritoneal cytology findings. Multivariable logistic regression analysis revealed that LOX expression, macroscopic type 4 cancers, T invasion (T2-T4), lymph node metastasis, hepatic metastasis, peritoneal metastasis, and peritoneal cytology findings were independent predictive parameters for the overall survival of patients (Table 2 ).
Discussion
In this study, the number of polygonal or spindle-shaped cells, indicating EMT, was increased by hypoxia in gastric cancer cells. Moreover, hypoxia decreased the level of the epithelial marker E-cadherin, and increased the level of the mesenchymal marker vimentin. Hypoxic conditions could affect the EMT of gastric cancer cells. We previously reported that hypoxia stimulated EMT of OCUM-2MD3 and OCUM-12 cells, and that TGFb receptor (TGFbR) inhibitor partially suppressed the EMT of OCUM-2MD3 and OCUM-12 cells [36] , which suggests that there exists another factor, besides TGFb/TGFbR signaling, responsible for the EMT of cancer cells in hypoxia. In this study, we found that not only TGFb signaling but also LOX affects the EMT of gastric cancer cells under hypoxic conditions. We focused on the role of LOX associated with the invasion ability of gastric cancer cells in this study. It has been reported that LOX families are associated with EMT signaling [25, 43, 44] . Thus, we examined the relationship between hypoxia-induced LOX and EMT in gastric cancer cells.
To investigate the role of LOX, we used two LOX siRNAs to knock down LOX mRNA in RT-PCR and anti-LOX antibody, which could detect the glycosylated LOX (about 58 kDa), the form of LOX before secretion, and mature LOX (about 30 kDa). We investigated the LOX knockdown in mRNA level by a primer set of LOX which is designed for sequences of LOX before secretion (pro-LOX) and mature LOX, not of LOX-PP. LOX knockdown inhibited the morphologic changes to polygonal or spindle shaped gastric cancer cells under hypoxia. In addition, under hypoxia, LOX knockdown upregulated CDH1 and downregulated VIM, which are recognized as processes involved in the mesenchymal-epithelial transition. These findings suggested that LOX is one of factors responsible for EMT of cancer cells in hypoxia. Several studies examining the relationship between LOX families and EMT previously reported that inactivation of LOX by baminopropionitrile, an active site inhibitor of LOX, also inhibited the hypoxia-induced EMT of cervical cancer cells [25] , and LOX induced by hypoxia was correlated with the expression of EMT markers, such as Snail [45] and Twist [46] . Furthermore, LOX-like 2 interacts with and stabilizes Snail 1, promoting CDH1 silencing, resulting in inducement of EMT [47, 48] . Further investigations are requited to clarify the expression of EMT inducers with LOX.
LOX expression of cancer cells was observed in the cytoplasm and nucleus, but mainly in the cytoplasm. LOX enters the cells and moves into nuclei in a manner that appears to be independent of its catalytic activity, as previously reported [49] . In this study, LOX-positive gastric cancer was found to be associated with tumor cell invasion, Lysyl oxidase is associated with the epithelial-mesenchymal transition of gastric cancer… 439 lymph node metastasis, lymphatic invasion, venous invasion, and peritoneal dissemination. LOX knockdown decreased the migration and invasion ability of cancer cells in vitro. Furthermore, we examined the expression of mature LOX in conditioned medium of gastric cancer cells, and showed that hypoxia increased the expression of mature LOX and that the influence of hypoxia was decreased by LOX knockdown, which explains that LOX is associated with invasive ability of gastric cancer cell not only by intracellular signaling but also by enzymatic activity in extracellular matrix. Gastric carcinoma patients with LOX expression have significantly poorer prognosis than those without LOX expression. Multivariate analysis revealed that overall survival correlated significantly with LOX expression. These findings suggest that LOX plays an important role for the invasion ability of gastric cancer cells, and that LOX is a useful predictive prognostic factor in patients with gastric cancer.
Many studies have shown that increased LOX expression is associated with malignant progression of cancer cells [17, 31, 50] , whereas some studies reported that 50-kDa pro-LOX or its cleaved 18-kDa product (LOX-PP) may have tumor-suppressive function [21] [22] [23] [24] . One of the reasons responsible for the differences between these reports and our study might be the different the cell lines. Another reason is that Kaneda et al. showed the upregulation of proliferative activities in vitro and in vivo by inactivation of LOX through methylation and loss of heterozygosity. In this study, we focused on the role of LOX associated with the invasive abilities of gastric cancer cells under hypoxia. Hypoxia was shown to upregulate protein expression of 58-kDa glycosylated LOX in cell lysates and 30-kDa mature LOX in conditioned medium. Upregulation of LOX increased the invasive abilities of OCUM2-MD3 and OCUM-12 cells. Knockdown of LOX diminished the hypoxic effect on EMT and invasive abilities. Tumor-suppressive activity of LOX in gastric cancer cells was unclear in this study, as we did not perform a cell proliferation assay or an in vivo assay, nor did we analyze the 18-kDa LOX-PP, a cleaved product from pro-LOX showing tumor-suppressor activities in prostate cancer [22] and breast cancer [24] . Our findings, however, suggest that LOX before secretion and/or the 30-kDa mature LOX might be associated with EMT and invasive abilities under hypoxic conditions in gastric cancer cells. An immunohistochemical study indicated that LOX expression was associated with a hypoxic microenvironment evaluated by CA9, and that it is overexpressed in response to tumor hypoxia in many common tumor types [51] [52] [53] [54] . We previously reported that the expression of CA9 might be associated with aggressive tumor phenotypes of gastric carcinomas [41] . Some studies have also demonstrated that LOX is a hypoxia-responsive gene correlated with the migration and invasion of cancer cells [25, 31, 32] . Together, these findings suggest that LOX expression is associated with the high invasion activity of gastric cancer under hypoxic conditions. Furthermore, HIFIA knockdown might downregulate the expression of LOX. In contrast, it has been reported that LOX is regulated by TGFb signaling [55] which is upreglated in hypoxic conditions [36] , which suggests that TGFb is also associated with LOX mRNA expression in hypoxic conditions.
In conclusion, LOX affects the EMT of gastric cancer cells under hypoxic conditions. LOX expression is a useful prognostic factor in patients with gastric cancer.
